ANTHEM BIOSCIENCES LTD

Operates a Contract Research, Development and Manufacturing Organization (CRDMO) that handles outsourced chemistry work for global pharma clients, alongside a smaller Speciality Ingredients business. CRDMO is the dominant earner at Rs 1,772.768 cr (83.5% of segment revenue) with segment EBIT of Rs 1,132.985 cr, covering custom synthesis, fermentation, and process development for both large-pharma and biotech customers, including molecules in late-phase clinical development. Speciality Ingredients contributed Rs 351.565 cr (16.5%) and Rs 179.065 cr in EBIT, supplying ingredients into food, nutraceutical and related end-markets. Total FY26 revenue stood at Rs 2,124.333 cr with a 45.4% EBITDA margin. The biggest input cost is raw materials at 33.6% of revenue, followed by employee cost at 13.3% and other operating expenses at 9.2%. Operations run across 3 plants with 2,282 permanent employees, and the company exports about 85% of its output.